期刊文献+

丙泊酚对HepG2肝母细胞瘤细胞侵袭能力的影响 被引量:3

Effects of propofol on the invasion ability of hepatoblastoma HepG2 cells
下载PDF
导出
摘要 目的:探讨丙泊酚对Hep G2肝母细胞瘤细胞侵袭能力的影响及相关机制。方法:用不同质量浓度(0、3、6、9和12 mg/L)丙泊酚培养Hep G2细胞24 h后,通过细胞侵袭实验检测侵袭率;培养24、48和72 h后用MTT法检测细胞活性;培养48 h后采用RT-PCR和Western blot法检测细胞中MMP-2、MMP-9 mRNA及MMP-2、MMP-9和TIMP-1蛋白的表达。结果:随丙泊酚质量浓度的增加,Hep G2细胞的侵袭能力逐渐降低(F=4 883.900,P<0.001),细胞活性逐渐降低(F=38.334,P<0.001),MMP-2及MMP-9 mRNA及蛋白的表达亦逐渐降低(P<0.05),而TIMP-1蛋白的表达逐渐升高(F=44.918,P<0.001)。结论:丙泊酚能降低Hep G2细胞的侵袭能力及细胞活性,其机制与抑制MMP-2和MMP-9蛋白的表达及促进TIMP-1蛋白的表达有关。 Aim: To investigate the effects and related mechanism of propofol on the invasion ability of Hep G2 cells.Methods: Different concentrations( 0,3,6,9 and 12 mg / L) of propofol were used to treat Hep G2 cells. The invasion ability was detected by Transwell after 24 h treatment; cell viability of Hep G2 cells was studied through MTT assay after 24,48,and 72 h treatment. The expressions of MMP-2,MMP-9 and TIMP-1 were measured through RT-PCR and Western blot after48 h treatment. Results: The invasion ability and cell viability of Hep G2 cells,the mRNA and protein expressions of MMP-2 and MMP-9,were significantly decreased with the increase of propofol concentration( P〈0. 05). The protein expression of TIMP-1 was significantly increased with the increase of propofol concentration( F = 44. 918, P〈0. 001). Conclusion: Propofol could reduce the invasive activity and cell viability of Hep G2 cells through the inhibition of MMP-2 and MMP-9,and overexpression of TIMP-1.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2015年第3期318-322,共5页 Journal of Zhengzhou University(Medical Sciences)
基金 国家自然科学基金青年项目81301308 81301040 陕西省自然科学基础研究计划项目2014JQ4158 陕西省青年科技新星项目2014KJXX-76
关键词 丙泊酚 肝母细胞瘤 MMP-2 MMP-9 TIMP-1 侵袭 propofol hepatoblastoma MMP-2 MMP-9 TIMP-1 invasion
  • 相关文献

参考文献18

  • 1Mammoto T,Mukai M, Mammoto A, et al. Intravenous an- esthetic, propofol inhibits invasion of cancer cells [ J ]. Cancer Lett ,2002,184 ( 2 ) : 165.
  • 2Wang P, Chen J, Mu LH, et al. Propofol inhibits invasion and enhances paclitaxel-induced apoptosis in ovarian canc- er cells through the suppression of the transcription factor slug [ J ]. Eur Rev Med Pharmacol Sci, 2013,17 ( 13 ) : 1722.
  • 3Zhang J, Zhang D, Wu GQ, et al. Propofol inhibits the ad- hesion of hepatocellular carcinoma ceils by upregulating microRNA-199a and downregulating MMP-9 expression [ J]. Hepatobiliary Pancreat Dis Int,2013,12( 3 ) :305.
  • 4Garib V, Lang K, Niggemann B, et al. Propofol-induced cal- cium signalling and actin reorganization within breast carci- noma cells [ J ]. Eur J Anaesthesiol, 2005,22 ( 8 ) : 609.
  • 5Miao Y, Zhang Y, Wan H, et al. GABA-receptor agonist, propofol inhibits invasion of colon carcinoma ceils [ J ]. Bi- omed Pharmacother,2010,64 ( 9 ) :583.
  • 6Coetzee JF, Glen JB, Wium CA, et al. Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets [ J ]. Anesthesiology, 1995,82(6) :1328.
  • 7Hoffmann K, Schmidt J. New surgical approaches in the treatment of hepatocellular carcinoma[ J ]. Z Gastroenterol, 2009,47( 1 ) :61.
  • 8刘叶,阮林,刘华.丙泊酚对肝癌细胞HepG2生物学行为的影响[J].临床麻醉学杂志,2013,29(5):491-494. 被引量:5
  • 9Kushida A, Inada T, Shingu K. Enhancement of antitumor immunity after propofol treatment in mice [ J ]. Immunop- harmacol Immunotoxicol, 2007,29 ( 3/4 ) : 477.
  • 10杨婉花,陈冰,李娟,原永芳.丙泊酚药物代谢动力学研究概述[J].中国药师,2008,11(10):1243-1246. 被引量:43

二级参考文献57

  • 1黄咏磊,张洁,张马忠,宋琳,王珊娟,杭燕南.持续输注丙泊酚药代动力学模型的选择[J].临床麻醉学杂志,2005,21(3):147-149. 被引量:9
  • 2许川雅,吴新民,蒋建渝,卢炜.国人老年患者靶控输注丙泊酚的群体药代动力学(英文)[J].Journal of Chinese Pharmaceutical Sciences,2005,14(3):154-161. 被引量:3
  • 3夏东亚,郭涛,宋丹丹,张洁,许霁虹,张铁铮.丙泊酚用于神经外科全身麻醉手术患者的药动学研究[J].中国药房,2007,18(14):1066-1067. 被引量:15
  • 4张优飞,方春锋,王汉桃,裘亚腾.芬太尼复合丙泊酚与氯化亚氮(笑气)在人工流产中的镇痛效果[J].中国药师,2007,10(5):483-484. 被引量:4
  • 5Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches [J].Anesthesiology, 1994, 80(1): 104-122
  • 6Vuyk J, Engbers FHM, Burn AGL, et al. Performance of computer-controlled infusion of propofol [J]. Anesth Analg, 1995,81:1275-1282
  • 7Vuyk J, Oostwouder C J, Vletter AA, et al. Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion[ J] . Br JAnaesth, 2001; 86:183
  • 8Schinder TW, Minto CF, Gambus PL, et al.The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers [J]. Anesthesiology, 1998, 88(5): 1170-1182
  • 9Shafer A, Doze VA, Shafer SL et al. Pharmacokinetics and pharmacodynamics of propofal infusions during general anesthesia[J]. A nesthesiology, 1988 , 69(3): 348-56
  • 10Murat I, Billard V, Vernois J, et al. Phannacokinefics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches [J]. Anesthesiology, 1996,84(3):526-532

共引文献50

同被引文献17

  • 1Brugires L, Branchereau S, Laithier V, et al. Pediatric malignant liver tumours [J]. Bull Cancer,2012,99 (2) : 219 - 228. DOI: 10. 1684/ bdc. 2011. 1539.
  • 2Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy [ J ]. Curr Opin Pediatr, 2014, 26 ( 1 ) : 19 - 28. DOI: 10. 1097/MOP. 06.
  • 3Meyers RL, Tiao G, Goyet JV, et al. Hepatoblastoma state of the art: pre- treatment extent of disease, surgical resection guidelines and the role of liver transplantation [ J ]. Curr Opin Pediatr, 2014,26 ( 1 ) : 29 - 36. DOI : 10. 1097/MOP. 2.
  • 4Hiyama E. Pediatric hepatoblastoma: diagnosis and treatment [ J]. Transl Pediatr,2014,3 (4) : 293 -299. DOI: 10. 3978/j. issn. 2224 - 4336. 2014.09.01.
  • 5Raquel V, Begnna S, Fernando BA, et al. Tuberculosis in pediatric solid organ and hepatopoietic stem cell transplant percipients [ J ]. Pediar Infect Disease J, 2012, 31 ( 7 ) : 774 - 777. DOI: 10. 1097/INF. 0b013e3182564ec7.
  • 6Matsunaga T, Sasaki F, Ohira M, et al. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma [ J ]. Pediatr Surg lnt,2003,19(5) :142 - 146. DOI:I0. 1007/s00383-002-0906-0.
  • 7Daniel CA, Piotr C, Rudolf M, et al. The treatment of hepatoblastoma : Its evolution and the current status as per the SIOPEL trials[ J]. J Indian Assoc Pediatr Surg, 2014, 19 (4) : 201 - 207. DOI: 10. 4103/0971- 9261. 142001.
  • 8Spector LG, Birch J. The epidemiology of hepatoblastoma [ J ]. Pediatr Blood Cancer,2012,59 (5) :776 - 779. DOI : 10. 1002/pbc. 24215.
  • 9Lautz TB, Ben-Ami T, Tantemsapya N, et al. Successful nontransplant resection of POST-TEXT m and IV hepatoblastoma[ J]. Cancer,2011, 117 (9) : 1976 - 1983. DOI : 10. 1002/cncr. 25722.
  • 10Ana Cristina AT, Lilian MC, Roberto Augusto PT, et al. New concepts and outcomes for children with hepatoblastoma based on the experience of a tertiary center over the last 21 years [ J]. Clinics (Sao Paulo), 2015,70(6) : 387 -392. DOI: 10. 6061/clinics/2015 (06)01.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部